If you have severe kidney disease, the answer is almost certainly no
However, it is important to note that retatrutide has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains an experimental treatment
What safety concerns are specific to the DPP-4 side of the pair
(Blue Zones lifestyle) Buil-Cosiales P, Zazpe I, Toledo E, Corella D, Salas-Salvad J, Diez-Espino J, Ros E, Fernandez-Creuet Navajas J, Santos-Lozano JM, Ars F, Fiol M, Castaer O, Serra-Majem L, Pint X, Lamuela-Ravents RM, Marti A, Basterra-Gortari FJ, Sorl JV, Verd-Rotellar JM, Basora J, Ruiz-Gutierrez V, Estruch R, Martnez-Gonzlez M